SCI时时刷

search
Biopharma dealmaking in 2024
Biopharma dealmaking in 2024
Discover the world’s best science and medicine | Nature.com
Outlook for medicines development and use in 2025
Oncology innovations, obesity medicines, an uptick for mergers and acquisitions, regulation for artificial intelligence ap...
Targeting mitophagy in neurodegenerative diseases
Targeting mitophagy in neurodegenerative diseases
Mitochondrial dysfunction is a hallmark of idiopathic neurodegenerative diseases, including Parkinson disease, amyotrophic...
Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
G protein-coupled receptors (GPCRs) are the largest human membrane protein family that transduce extracellular signals int...
2024 FDA approvals
2024 FDA approvals
The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine and ...
Chemical engineering of CRISPR–Cas systems for therapeutic application
Chemical engineering of CRISPR–Cas systems for therapeutic application
Clustered regularly interspaced short palindromic repeats (CRISPR) technology has transformed molecular biology and the fu...
Open Targets: 10 years of partnership in target discovery
The Open Targets consortium was founded in 2014 to translate insights from genetics and functional genomics into identifyi...
Harnessing the biology of regulatory T cells to treat disease
Harnessing the biology of regulatory T cells to treat disease
Regulatory T (Treg) cells are a suppressive subset of CD4+ T cells that maintain immune homeostasis and restrain inflammat...
IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases
New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer...
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer
The importance of metabolic pathways in regulating immune responses is now well established, and a mapping of the bioenerg...
NaV1.8 inhibitor poised to provide opioid-free pain relief
NaV1.8 inhibitor poised to provide opioid-free pain relief
Vertex’s first-in-class suzetrigine could soon usher in a new class of analgesic.
Top product forecasts for 2025
Discover the world’s best science and medicine | Nature.com
Can non-canonical amino acids open up non-canonical drug discovery opportunities?
Can non-canonical amino acids open up non-canonical drug discovery opportunities?
Jason Chin, head of Cambridge’s Centre for Chemical & Synthetic Biology and CSO of Constructive Bio, discusses the rol...
Showing tau the exit
Discover the world’s best science and medicine | Nature.com
Antiviral target compound profile for pandemic preparedness
The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies dedicated to accelerating t...